Log In
BCIQ
Print this Print this
 

Sarcoma vaccine

  Manage Alerts
Collapse Summary General Information
Company MabVax Therapeutics Holdings Inc.
DescriptionVaccine including antigens targeting ganglioside GM2, GD2 and GD3 and conjugated with the keyhole limpet hemocyanin (KLH) plus a saponin adjuvant
Molecular Target Ganglioside GM2 (GM2) ; GD3 ganglioside
Mechanism of ActionVaccine
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationSarcoma
Indication DetailsPrevent recurrent sarcoma; Treat sarcoma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/09/2014

Undisclosed

0

0

Get a free BioCentury trial today